HUP9702039A2 - Ösztrogén agonisták/antagonisták alkalmazása atherosclerosis kezelésére alkalmas gyógyszerkészítmények előállítására - Google Patents

Ösztrogén agonisták/antagonisták alkalmazása atherosclerosis kezelésére alkalmas gyógyszerkészítmények előállítására

Info

Publication number
HUP9702039A2
HUP9702039A2 HU9702039A HUP9702039A HUP9702039A2 HU P9702039 A2 HUP9702039 A2 HU P9702039A2 HU 9702039 A HU9702039 A HU 9702039A HU P9702039 A HUP9702039 A HU P9702039A HU P9702039 A2 HUP9702039 A2 HU P9702039A2
Authority
HU
Hungary
Prior art keywords
production
estrogen agonist
antagonists
inhibition
against atherosclerosis
Prior art date
Application number
HU9702039A
Other languages
English (en)
Inventor
Robert Joseph Aiello
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HU9702039D0 publication Critical patent/HU9702039D0/hu
Publication of HUP9702039A2 publication Critical patent/HUP9702039A2/hu
Publication of HUP9702039A3 publication Critical patent/HUP9702039A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Eljárás gyógyszerkészítmény előállítására, az atherőxclerősiskezelésére, a lipid csökkentéstől függetlenül, emlősökben, ideértve azembert, őlyan esetekben, ahől szükség van egy atherőgén lézióprőgressziójának gátlására vagy plakkstabilizálásra. Az ilyen lézióprőgresszió gátlást vagy plakkstabilizálást előnyösen a túlzőttgyűlladásős sejt felépüléshez vezető kemőkin expresszió közvetlengátlásával érhetik el, bizőnyős ösztrőgén agőnista/antagőnistavegyületek alkalmazásának segítsé- gével, mint 4-hidrőxi-tamőxifén,tamőxifén, ralőxifén, tőremifén, centchrőman, időxifén és másők. ŕ
HU9702039A 1996-11-15 1997-11-14 Use of estrogen agonist/antagonists for the production of medicaments against atherosclerosis HUP9702039A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3127596P 1996-11-15 1996-11-15

Publications (3)

Publication Number Publication Date
HU9702039D0 HU9702039D0 (en) 1998-01-28
HUP9702039A2 true HUP9702039A2 (hu) 1999-06-28
HUP9702039A3 HUP9702039A3 (en) 1999-07-28

Family

ID=21858562

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9702039A HUP9702039A3 (en) 1996-11-15 1997-11-14 Use of estrogen agonist/antagonists for the production of medicaments against atherosclerosis

Country Status (11)

Country Link
US (2) US6069175A (hu)
EP (1) EP0843999A1 (hu)
JP (1) JPH10147522A (hu)
KR (1) KR19980042434A (hu)
AU (1) AU735617B2 (hu)
CA (1) CA2221091C (hu)
HU (1) HUP9702039A3 (hu)
IL (1) IL122124A (hu)
MY (1) MY117009A (hu)
NZ (1) NZ329188A (hu)
ZA (1) ZA9710295B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
WO2002047723A1 (fr) * 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicamenteuses presentant une meilleure hydrosolubilite
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
ITRM20010695A1 (it) * 2001-11-26 2003-05-26 Sigma Tau Ind Farmaceuti Uso della propionil l-carnitina o di un suo sale farmacologicamente accettabile per la preparazione di un medicamento per il trattamento del
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
US20050119324A1 (en) * 2003-09-24 2005-06-02 Wyeth Methods of treating atherosclerosis using NF-kB inhibitors
JP6273902B2 (ja) * 2014-02-28 2018-02-07 日立化成株式会社 二次電池

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE4320898A1 (de) * 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
PT1095654E (pt) * 1993-12-21 2004-04-30 Lilly Co Eli Utilizacao de raloxifeno e dos seus analogos para a manufactura de um medicamento para a inibicao da oxidacao de ldl e aterosclerose
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
CA2208859A1 (en) * 1995-01-13 1996-07-18 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療

Also Published As

Publication number Publication date
AU4518597A (en) 1998-05-21
HUP9702039A3 (en) 1999-07-28
US6124346A (en) 2000-09-26
CA2221091C (en) 2002-05-28
KR19980042434A (ko) 1998-08-17
HU9702039D0 (en) 1998-01-28
JPH10147522A (ja) 1998-06-02
MY117009A (en) 2004-04-30
IL122124A (en) 2002-11-10
EP0843999A1 (en) 1998-05-27
NZ329188A (en) 2000-08-25
CA2221091A1 (en) 1998-05-15
AU735617B2 (en) 2001-07-12
US6069175A (en) 2000-05-30
ZA9710295B (en) 1999-05-14
IL122124A0 (en) 1998-04-05

Similar Documents

Publication Publication Date Title
HUP9702039A2 (hu) Ösztrogén agonisták/antagonisták alkalmazása atherosclerosis kezelésére alkalmas gyógyszerkészítmények előállítására
BG102668A (en) Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
MA27265A1 (fr) Formulations d'agoniste opioide a antagoniste liberable et sequestre
NO951613L (no) Ikke-peptidyl tachykinin reseptorantagonister
FI953748A (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
CO5560558A2 (es) Uso de una composicion de celecoxib para rapido alivio del dolor
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
GB9807639D0 (en) Anti-inflammatory agents
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
ME00416B (me) Celekoksibne smješe
ES8505519A1 (es) Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos.
BR9911046A (pt) Uso de antidepressivos tricìclicos para analgesia local
CL2004000643A1 (es) Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana.
EP1428821A8 (en) Piperidin-4-yl amines with analgesic effect
IE822500L (en) PHARMACEUTICALLY ACTIVE 1, 2, 3, 4, 4a, 5, 10, 10a, -¹OCTAHYDROBENZO£g| QUINOLINE DERIVATIVES
IL125794A (en) Pharmaceutical composition based on rhein or diacerhein with improved bioavailability
PT946176E (pt) Utilizacao de derivados de acido 7-(2-oxa-5,8-diazabiciclo¬4.3.0|non-8-il)-quinolonacarboxilico e -naftiridonacarboxilico para terapia de infeccoes por helicobacter pylori e das doencas gastroduodenais a elas associadas
IS4553A (is) Lyfjablöndur sem innihalda mónóamín oxídasa B blokkara
NO984330D0 (no) Benzopyranderivater som har leukotrien-antagonistisk virkning
DK1185267T3 (da) Dermale bedövelsesmidler
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
ATE309811T1 (de) Analgetikum aus schlangengift